U.S. FDA advisers back Ardelyx’s kidney disease drug

(Reuters) -A panel of advisers to the U.S. Food and Drug Administration on Wednesday recommended the approval of Ardelyx Inc’s drug for chronic kidney disease patients on dialysis, more than a year after the regulator had rejected it.